Dr. Robert Alan Nagourney is a distinguished Hematology and Medical Oncology specialist based in Long Beach, California. Graduating with honors in 1979, he brings over four decades of diverse experience to the forefront of cancer treatment and research. Dr. Nagourney is board certified in Internal Medicine, Medical Oncology, and Hematology, holding medical licenses in both California and Virginia.

As the Medical and Laboratory Director of The Nagourney Cancer Institute and an Associate Clinical Professor at the University of California, Irvine, he has dedicated his career to pioneering personalized cancer treatment. He is internationally recognized for his groundbreaking work in developing "functional profiling," a method that uses a patient's own living cancer cells to predict how they will respond to treatment before it is administered.

His focus on the laboratory study of cancer cell death, known as apoptosis, has provided a robust and reliable method for predicting patient response and improving survival outcomes. This innovative approach is at the core of the EVA-PCD assay, a technology he developed to measure the effectiveness of chemotherapy, targeted agents, and novel drug combinations.

Dr. Nagourney is a prolific author, with over 100 manuscripts, book chapters, and abstracts published in major peer-reviewed journals such as the Journal of Clinical Oncology, Cancer Research, and the British Journal of Cancer. His work continues to shape the future of oncology, moving it away from a one-size-fits-all model to a truly personalized, patient-centered approach.